Site notifications

Sub menu

 
 

Ozempic (semaglutide) shortage collection

There is a worldwide shortage of this diabetes medicine. TGA alerts relate to the shortage in Australia.

Increased global demand for semaglutide products is impacting availability of Ozempic (semaglutide) in Australia. Alerts on the shortage of Trulicity (dulaglutide) and Mounjaro (tirzepatide) are also accessible from this collection.

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Type

Topics

Audiences

Read current information and updates at:
About the Ozempic (semaglutide) shortage 2022 and 2024
About the Trulicity (dulaglutide) shortage 2022 and 2023

The pharmaceutical company that supplies Ozempic, Novo Nordisk, has recently advised the TGA and the Ozempic Medicine Shortage Action Group that supply throughout the rest of the year and into 2024 will be limited. Currently we are asking health professionals not to prescribe Ozempic to new patients to conserve supply for patients who are already stabilised on this medicine and who do not have suitable alternatives.

Visit the Medicine shortage reports database to search for all medicines in shortage and find information about management actions.

14 result(s) found, displaying 1 to 10

  • Counterfeit Ozempic pens detected and adverse event reported

    Safety alerts
    Consumers and health professionals should be aware that counterfeit Ozempic-labelled pens have been imported into Australia. These pens may pose a serious health risk and should not be used. There are clear inconsistencies from the original product to look out for.

  • New semaglutide product becomes available

    Medicine shortage alerts
    Pharmaceutical company Novo Nordisk has advised us that a new brand of semaglutide approved for chronic weight management, Wegovy, will be available in Australia from early August 2024.

  • Compounding safety information: semaglutide-like products

    Safety alerts
    We are aware of an emerging trend for telehealth providers to offer compounded semaglutide-like products. Compounded semaglutide-like products are ‘unapproved’ therapeutic goods and have not been evaluated by us for safety, quality and efficacy.

  • Shortage of Mounjaro (tirzepatide) injections

    Medicine shortage alerts
    The availability of all strengths of Mounjaro (tirzepatide) will be limited until 31 August 2024, due to unexpected high demand. Patients and healthcare professionals should check the Medicine Shortage Reports Database for the latest supply information.

  • Ozempic (semaglutide) supply update

    Medicine shortage alerts
    The supply of Ozempic (semaglutide) in Australia is improving however the shortage continues. Stay updated about how the shortage impacts you.

  • Counterfeit semaglutide vials

    Safety alerts
    The TGA has detected fake semaglutide, also known as Ozempic, being illegally imported into Australia.

  • Consumers warned about Ozempic scams

    Media releases
    The TGA is aware of several scams targeting consumers seeking semaglutide (Ozempic). Consumers are strongly advised not to use products unless they have come from a trusted source.

Help us improve the Therapeutic Goods Administration site